Penumbra Inc (NYSE:PEN) insider James Robert Pray sold 8,125 shares of the business’s stock in a transaction that occurred on Monday, July 30th. The stock was sold at an average price of $138.34, for a total value of $1,124,012.50. Following the completion of the transaction, the insider now directly owns 1,578 shares in the company, valued at $218,300.52. The sale was disclosed in a legal filing with the SEC, which is available through this link.
James Robert Pray also recently made the following trade(s):
Get Penumbra alerts:
On Monday, July 23rd, James Robert Pray sold 8,125 shares of Penumbra stock. The stock was sold at an average price of $141.86, for a total value of $1,152,612.50.
Penumbra traded down $1.90, hitting $143.00, during trading hours on Thursday, Marketbeat.com reports. 610 shares of the stock were exchanged, compared to its average volume of 316,373. Penumbra Inc has a twelve month low of $78.90 and a twelve month high of $167.35. The company has a market cap of $4.87 billion, a price-to-earnings ratio of -14,490.00, a P/E/G ratio of 43.11 and a beta of 0.15.
Penumbra (NYSE:PEN) last posted its quarterly earnings data on Tuesday, May 8th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.08. Penumbra had a return on equity of 1.13% and a net margin of 3.65%. The firm had revenue of $102.70 million for the quarter, compared to the consensus estimate of $90.98 million. During the same quarter in the prior year, the business earned ($0.10) EPS. The business’s revenue for the quarter was up 40.3% compared to the same quarter last year. analysts forecast that Penumbra Inc will post 0.17 EPS for the current fiscal year.
Several research analysts have issued reports on PEN shares. Goldman Sachs Group started coverage on Penumbra in a report on Wednesday, April 4th. They set a “buy” rating and a $145.00 price objective on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $125.00 price objective on shares of Penumbra in a report on Thursday, April 5th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $180.00 price objective (up previously from $150.00) on shares of Penumbra in a report on Thursday, May 31st. BMO Capital Markets upped their price objective on Penumbra from $115.00 to $140.00 and gave the stock a “market perform” rating in a report on Wednesday, May 9th. Finally, Zacks Investment Research downgraded Penumbra from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 12th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Penumbra has a consensus rating of “Buy” and an average price target of $161.20.
A number of large investors have recently bought and sold shares of the business. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Penumbra during the 2nd quarter worth $6,031,000. Gilder Gagnon Howe & Co. LLC raised its position in shares of Penumbra by 27.5% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 7,701 shares of the company’s stock valued at $1,064,000 after acquiring an additional 1,659 shares during the last quarter. Leavell Investment Management Inc. raised its position in shares of Penumbra by 35.0% during the 2nd quarter. Leavell Investment Management Inc. now owns 2,700 shares of the company’s stock valued at $373,000 after acquiring an additional 700 shares during the last quarter. Fred Alger Management Inc. bought a new stake in shares of Penumbra during the 2nd quarter valued at $1,913,000. Finally, Amalgamated Bank raised its position in shares of Penumbra by 82.7% during the 2nd quarter. Amalgamated Bank now owns 7,151 shares of the company’s stock valued at $988,000 after acquiring an additional 3,238 shares during the last quarter. 74.72% of the stock is currently owned by hedge funds and other institutional investors.
Penumbra Company Profile
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Featured Article: What is a Leveraged Buyout (LBO)?